Ane Appelt, Associate Professor in Radiotherapy Physics at the University of Leeds, shared a post on X:

“Important (and puzzling) results from the Skagen Trial 1: Moderate hypofractionation for high-risk (node-positive) breast cancer patients does not increase arm lymphoedema – but is *does* seem to increase the breast-cancer related mortality.

Why? Not quite clear, but Prof Offersen speculates that the effective dose might simply be too low with 40Gy/15# for this group. (They’ve carefully confirmed that it’s not a question of RT quality!)”

Skagen Trial

ESTRO 2025 Live Updates on OncoDaily.

SKAGEN Trial 1 at ESTRO 2025: Moderately Hypofractionated RT Safe, But Mortality Signal Warrants Caution

Ane Appelt: Important results from the Skagen Trial 1 presented at ESTRO 2025

“Important (and puzzling) results from the Skagen Trial 1: Moderate hypofractionation for high-risk (node-positive) breast cancer patients does not increase arm lymphoedema – but is does seem to increase the breast-cancer related mortality.

Why? Not quite clear, but Prof Offersen speculates that the effective dose might simply be too low with 40Gy/15# for this group. (They’ve carefully confirmed that it’s not a question of RT quality!)”